226
Participants
Start Date
June 30, 2016
Primary Completion Date
March 14, 2017
Study Completion Date
March 14, 2017
CR845 0.5 mcg/kg
IV medication delivered three times/week
CR845 1 mcg/kg
IV medication delivered three times/week
CR845 1.5mcg/kg
IV medication delivered three times/week
Placebo
IV medication delivered three times/week
Cara Therapeutics Study Site, College Point
Cara Therapeutics Investigator Site, Mineola
Cara Therapeutics Study Site, Bethlehem
Cara Therapeutics Investigator Site, Philadelphia
Cara Therapeutics Study Site, Winston-Salem
Cara Therapeutics Investigator Site, Wilmington
Cara Therapeutics Study Site, Augusta
Cara Therapeutics Study Site, Winter Park
Cara Therapeutics Study Site, Hollywood
Cara Therapeutics Study Site, Tampa
Cara Therapeutics Study Site, Chattanooga
Cara Therapetics Study Site, Knoxville
Cara Therapeutics Study Site, Milwaukee
Cara Therapetics Study Site, Creve Coeur
Cara Therapeutics Study Site, Kansas City
Cara Therapeutics Study Site, Kansas City
Cara Therapeutics Study Site, Omaha
Cara Therapeutics Study Site, Pine Bluff
Cara Therapeutics Study Site, San Antonio
Cara Therapeutics Study Site, San Antonio
Cara Therapeutics Study Site, San Antonio
Cara Therapeutics Study Site, Denver
Cara Therapeutics Study Site, Meridian
Cara Therapeutics Investigator Site, Phoenix
Cara Therapetics Investigator Site, Albuquerque
Cara Therapeutics Study Site, Gallup
Cara Therapeutics Study Site, Whittier
Cara Therapeutics Investigator Site, Long Beach
Cara Therapeutics Study Site, Northridge
Lead Sponsor
Cara Therapeutics, Inc.
INDUSTRY